文献速递瓣膜外科

Perceval无缝合生物瓣主动脉瓣置换617例单中心经验

Aortic Valve Replacement With Perceval Bioprosthesis: Single-Center Experience With 617 Implants.
PubMed 文献 · Ann Thorac Surg · 2017-09-28

本研究回顾性分析617例接受Perceval无缝合主动脉瓣生物瓣置换患者的临床与超声心动图结局。30天死亡率为1.9%,平均随访16.3个月生存率91.3%,免于再手术率99%,平均跨瓣压差11.9±5.4 mmHg。结论认为该技术死亡率低、血流动力学性能优良,或可缩短手术时间并便于微创开展。

要点

  • 617例Perceval瓣置换,30天死亡率1.9%(12/617)。
  • 平均随访16.3个月生存率91.3%,免于再手术率99%。
  • 平均跨瓣压差11.9±5.4 mmHg,左室质量指数显著下降(p<0.001)。

核心结论

  • Perceval无缝合生物瓣行主动脉瓣置换与低死亡率及优良血流动力学性能相关。
  • 无缝合技术可能缩短手术时间,尤其在合并手术中,并使微创主动脉瓣置换更易可重复开展。

研究设计与样本

  • 单中心回顾性队列研究,2011年3月至2015年12月共617例患者接受Perceval生物瓣主动脉瓣置换。
  • 平均年龄76±7岁,女性388例(63%),平均EuroSCORE II为6.2%±5.4%。
  • 合并手术包括二尖瓣手术(n=74)、三尖瓣修复(n=22)、冠状动脉旁路移植(n=42)、心肌切除术(n=3)及升主动脉替换(n=2)。

主要发现

  • 30天死亡率为1.9%(12/617)。
  • 516例单纯主动脉瓣置换中475例(92%)接受微创手术,其中上段小胸骨切开81例、右前小切口开胸394例。
  • 单纯主动脉瓣置换的体外循环时间81.7±29.1分钟、主动脉阻断时间50.5±19.8分钟;合并手术分别为139.7±51.5分钟和91.5±29.5分钟。
  • 平均随访16.3个月(范围0至51.9个月),生存率91.3%,免于再手术率99%,平均跨瓣压差11.9±5.4 mmHg。
  • 左室射血分数从53.6%±8.4%变为54.5%±4.8%(p=0.40),左室质量从146.5降至112.6 g/m2(p<0.001),3例出现中度瓣周漏但无溶血且无需治疗。

临床怎么用

  • 对于适合行主动脉瓣置换的患者,Perceval无缝合瓣可考虑作为生物瓣选择之一,尤其利于微创入路和合并手术中缩短手术时间。
  • 术后需关注瓣周漏,但本研究显示中度瓣周漏发生率低且多无需干预。

局限性

  • 单中心回顾性设计,随访时间较短(平均16.3个月),缺乏与其他瓣膜类型的对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study describes the clinical and echocardiographic outcomes in a large single-center cohort of patients who underwent aortic valve replacement (AVR) with a sutureless Perceval (LivaNova, Milan, Italy) aortic bioprosthesis. METHODS: Between March 2011 and December 2015, 617 patients underwent AVR with a Perceval bioprosthesis. The mean age was 76 ± 7 years, 388 patients were female (63%), and the mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was 6.2% ± 5.4%. Concomitant procedures were mitral valve surgery (n = 74), tricuspid valve repair (n = 22), coronary artery bypass grafting (n = 42), myectomy (n = 3), and ascending aorta replacement (n = 2). RESULTS: The 30-day mortality rate was 1.9% (12 of 617). A total of 475 of 516 (92%) patients who had isolated AVR underwent minimally invasive surgery with an upper ministernotomy (n = 81) or a right anterior minithoracotomy (n = 394) approach. Cardiopulmonary bypass and aortic cross-clamp times were 81.7 ± 29.1 minutes and 50.5 ± 19.8 minutes for isolated AVR and 139.7 ± 51.5 minutes and 91.5 ± 29.5 minutes for combined procedures, respectively. At mean follow-up of 16.3 months (range, 0 to 51.9 months), the survival rate was 91.3%, the rate of freedom from reoperation was 99%, and the mean transvalvular pressure gradient was 11.9 ± 5.4 mm Hg. Left ventricular ejection fraction increased from 53.6% ± 8.4% to 54.5% ± 4.8% (p = 0.40), left ventricular mass decreased from 146.5 to 112.6 g/m2 (p < 0.001), and moderate paravalvular leakage occurred in 3 patients without hemolysis who did not require any treatment. CONCLUSIONS: AVR with the Perceval bioprosthesis is associated with low mortality rates and excellent hemodynamic performance. Sutureless technology may reduce operative times, especially in combined procedures, and may make minimally invasive AVR more easily reproducible.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Concistrè G, Chiaramonti F, Bianchi G, et al. Aortic Valve Replacement With Perceval Bioprosthesis: Single-Center Experience With 617 Implants. Ann Thorac Surg. 2017. PMID: 28964415. doi:10.1016/j.athoracsur.2017.05.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。